Semester 7
BP702T
Pilot Plant Scale-Up Techniques
This unit covers the critical transition from laboratory-scale formulation to full-scale manufacturing. It addresses general considerations for pilot plant operations (personnel, space, equipment, raw materials), specific scale-up challenges for different dosage forms (solids, liquid orals, semi-solids), documentation requirements, SUPAC (Scale-Up and Post-Approval Changes) guidelines, and an introduction to platform technology for streamlined pharmaceutical development.
Syllabus & Topics
- 1Pilot Plant – Introduction: Pilot plant: an intermediate-scale manufacturing facility used to translate laboratory formulations into production-scale processes. Purpose: (1) Bridge the gap between R&D (grams) and production (kg/tons). (2) Identify and solve scale-up problems BEFORE full-scale manufacturing. (3) Produce clinical trial batches. (4) Validate process parameters. (5) Generate data for regulatory submissions (scale-up data required in NDA/ANDA). (6) Train production personnel. Scale: typically 1/10th of production scale (e.g., if production batch = 100,000 tablets, pilot batch = 10,000 tablets). Minimum pilot scale for regulatory submissions: 1/10th of production OR 100,000 units, whichever is larger (FDA guidance).
- 2General Considerations – Personnel: Personnel requirements: (1) Qualified and experienced staff — pharmacists, chemical engineers, process engineers. (2) Understanding of BOTH R&D (formulation science) and production (equipment, process). (3) Key roles: pilot plant manager, process development scientist, analytical chemist, validation engineer, quality assurance. (4) Training: staff must be trained on GMP, equipment operation, SOPs, safety, documentation. (5) Communication skills: pilot plant team acts as LIAISON between R&D and production — must effectively communicate findings to both. (6) Cross-functional collaboration: work with QA, QC, regulatory affairs, engineering departments.
- 3General Considerations – Space & Raw Materials: Space requirements: (1) Adequate floor space for equipment installation, material staging, and personnel movement. (2) Separate areas: receiving, storage, dispensing, manufacturing, packaging, QC laboratory, documentation room. (3) Meet GMP requirements: smooth floors/walls, adequate HVAC, clean room classification as needed. (4) Flexibility: pilot plant should accommodate multiple dosage forms and scale changes. (5) Utilities: purified water, compressed air, vacuum, steam, electricity. Raw materials: (1) Same grade and specifications as production-scale materials (not research-grade). (2) Vendor qualification: same approved vendors as production. (3) Sufficient quantity for multiple pilot batches (minimum 3 for validation). (4) Storage conditions identical to production warehouse. (5) Analysis by QC before use. (6) Key consideration: raw material variability between batches can cause scale-up failures — characterize multiple lots.
- 4Scale-Up for Solid Dosage Forms: Tablets — critical scale-up parameters: (1) Mixing/Blending: lab → V-blender, ribbon blender, bin blender. Scale-up rule: fill volume ratio must remain constant (typically 50-70% fill). Mixing time increases but NOT proportionally — over-mixing can cause demixing. Tip speed (peripheral velocity) often kept constant. Sampling strategy changes at larger scale. (2) Granulation: wet granulation scale-up — binder addition rate, impeller/chopper speed, granulation endpoint (power consumption, amperage). High-shear granulator: Froude number (Fr = n²d/g) used for scale-up. Fluid bed granulation: air volume, inlet air temperature, spray rate. (3) Drying: fluid bed dryer — air volume, temperature, moisture endpoint (LOD). Tray dryer → different drying kinetics at scale. (4) Compression: rotary tablet press — turret speed, pre-compression/main compression forces, dwell time, feeder speed, weight/hardness variation. Tablet tooling selection critical at scale.
- 5Scale-Up for Liquid Orals: Solutions, suspensions, emulsions — scale-up challenges: (1) Mixing: lab uses magnetic stirrer/homogenizer. Production uses propeller/turbine mixers, inline mixers, homogenizers. Scale-up parameters: tip speed (πND), Reynolds number (Re = ρND²/μ), power number. Keep geometric similarity (ratio of impeller diameter to tank diameter constant). Baffles required at production scale to prevent vortex formation. (2) Heating/Cooling: heat transfer changes — surface area to volume ratio DECREASES at larger scale → slower heating/cooling. May need jacketed vessels, heat exchangers. (3) Dissolution: dissolving solids takes longer at scale — agitation intensity and time adjustment needed. (4) Emulsification: homogenization pressure and number of passes — shear rate must be maintained. Droplet size distribution must match lab-scale product. (5) Suspension: particle size distribution, viscosity, zeta potential monitoring during scale-up. Settling behavior may differ at scale.
- 6Scale-Up for Semi-Solids: Ointments, creams, gels — scale-up considerations: (1) Mixing/Homogenization: lab — mortar/pestle, homogenizer. Production — planetary mixer, sigma blade mixer, triple roller mill, high-shear mixer. Shear rate and shear stress must be controlled — affects rheology and product quality. Temperature control critical during mixing (creams: oil phase + aqueous phase mixing temperature). (2) Phase mixing (creams/emulsions): order of addition of phases, rate of addition, temperature during mixing — all critical. Emulsion stability depends on energy input during formation. (3) Cooling: rate of cooling after emulsification significantly affects crystal size, consistency, and stability. Larger batches cool SLOWER (lower SA/V ratio) → may need forced cooling. (4) Filling: viscosity changes affect fill accuracy. Semi-automatic to automatic filling equipment. Air entrapment during mixing — vacuum mixing preferred at scale. Deaeration step may be needed.
- 7Scale-Up Documentation: Documentation at pilot plant level: (1) Technology Transfer Document: formulation details, process flow, critical parameters, specifications. (2) Pilot Batch Manufacturing Record: like BMR but for pilot batch — all process steps, actual parameters, deviations. (3) Analytical Data: in-process and finished product testing results. (4) Stability Data: accelerated and long-term stability of pilot batches (required for regulatory submission). (5) Validation Protocol: prospective validation of at least 3 pilot batches. (6) Scale-Up Report: summary of scale-up rationale, parameters adjusted, results, recommendations for production. (7) Deviation Reports: any unexpected observations during scale-up. (8) Equipment Qualification Records: IQ/OQ/PQ of pilot plant equipment. All documentation must meet GMP standards — reviewed and approved by QA.
- 8SUPAC Guidelines: SUPAC (Scale-Up and Post-Approval Changes): FDA guidance documents for managing post-approval changes in manufacturing. Types: SUPAC-IR (Immediate Release), SUPAC-MR (Modified Release), SUPAC-SS (Semi-Solids). Change Levels: Level 1 (Minor): changes unlikely to affect product quality. Examples: ±5% excipient change (non-critical), minor equipment change (same design/operating principle). Requirements: annual report notification. Level 2 (Moderate): changes that COULD affect quality. Examples: ±10% excipient change, different equipment design, different site (same company). Requirements: supplement (CBE-30) + dissolution testing ± stability. Level 3 (Major): changes LIKELY to affect quality. Examples: >10% excipient change, change in synthesis route, different site (different company). Requirements: prior approval supplement + dissolution + stability + possible bioequivalence study.
- 9SUPAC – Specific Changes & Platform Technology: SUPAC categories of changes: (1) Components and composition. (2) Manufacturing site. (3) Manufacturing process (batch size, equipment). (4) In-process controls. Each change classified as Level 1, 2, or 3 with specific testing requirements. Example: tablet compression — changing from one rotary press to another of same design/principle = Level 1. Changing from rotary press to a completely different compression technology = Level 2 or 3. SUPAC significance: provides PREDICTABILITY — manufacturers know exactly what testing is needed for each type of change. Reduces regulatory burden for minor changes. Platform Technology: a set of proven manufacturing processes, equipment, and formulation strategies that can be applied across multiple products. Reduces development time, leverages existing knowledge, minimizes risk. Example: a company with validated fluid bed granulation platform can apply its knowledge (granulation parameters, drying endpoints, process controls) to new products → faster development. QbD and platform technology are closely linked — understanding design space enables platform approaches.
Learning Objectives
Pilot Plant Purpose: Explain the objectives of a pilot plant and its role in bridging R&D and production.
Solid Scale-Up: Describe scale-up considerations for tablet manufacturing including mixing, granulation, and compression.
SUPAC Levels: Compare Level 1, 2, and 3 changes with examples and required documentation for each.
Liquid Scale-Up: Explain why heat transfer and mixing behave differently at production scale vs laboratory scale.
Platform Technology: Define platform technology and explain how it relates to QbD.
Exam Prep Questions
Q1. Why can’t we directly go from lab scale to production scale?
Many parameters do NOT scale linearly. At lab scale: small volumes (100 mL-1 L), uniform mixing is easy, heat transfer is fast (high surface area to volume ratio), manual operations work. At production scale (100-1000 L): mixing becomes uneven (dead zones, poor mass transfer), heat transfer is slow (low SA/V ratio), equipment dynamics change completely (different shear rates, different flow patterns), and raw material variability matters more. Without a pilot plant step, production batches would have high failure rates, wasting expensive materials and time.
Q2. What is the Froude number in granulation scale-up?
Froude number (Fr) = n²d/g, where n = impeller speed (rev/s), d = impeller diameter (m), g = acceleration due to gravity (9.81 m/s²). In high-shear granulation, keeping Froude number constant during scale-up maintains similar powder flow patterns. The logic: Froude number represents the ratio of centrifugal force to gravitational force. If the powder movement pattern (throwing, cascading) is the same at both scales, the granulation will behave similarly. However, Froude number alone is often insufficient — tip speed and specific energy input are also considered.
Q3. What is the difference between SUPAC-IR and SUPAC-MR?
SUPAC-IR: for Immediate Release solid oral dosage forms (conventional tablets, capsules). Changes assessed primarily by dissolution testing (since drug release is relatively simple).
SUPAC-MR: for Modified Release products (extended release, delayed release). More stringent requirements because release mechanism is complex and highly sensitive to formulation and process changes. Level 2-3 changes in SUPAC-MR more likely to require bioequivalence studies compared to SUPAC-IR, because even small changes can significantly alter the release profile.